APA

Charmsaz S., Al-Ejeh F., Yeadon T. M., Miller K. J., Smith F. M., Stringer B. W., Moore A. S., Lee F., Cooper L. T., Stylianou C., Yarranton G. T., Woronicz J., Scott A. M., Lackmann M. & Boyd A. W. (20171009). EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia. : Leukemia.

Chicago

Charmsaz S, Al-Ejeh F, Yeadon T M, Miller K J, Smith F M, Stringer B W, Moore A S, Lee F-T, Cooper L T, Stylianou C, Yarranton G T, Woronicz J, Scott A M, Lackmann M and Boyd A W. 20171009. EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia. : Leukemia.

Harvard

Charmsaz S., Al-Ejeh F., Yeadon T. M., Miller K. J., Smith F. M., Stringer B. W., Moore A. S., Lee F., Cooper L. T., Stylianou C., Yarranton G. T., Woronicz J., Scott A. M., Lackmann M. and Boyd A. W. (20171009). EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia. : Leukemia.

MLA

Charmsaz S, Al-Ejeh F, Yeadon T M, Miller K J, Smith F M, Stringer B W, Moore A S, Lee F-T, Cooper L T, Stylianou C, Yarranton G T, Woronicz J, Scott A M, Lackmann M and Boyd A W. EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia. : Leukemia. 20171009.